
Alpha blockers
Alpha blockers are pharmaceutical compounds that work by inhibiting the activity of alpha-adrenergic receptors, which are responsible for the contraction of smooth muscles. These medications are commonly used to treat conditions such as high blood pressure and benign prostatic hyperplasia by causing blood vessels to relax and widen. At CymitQuimica, we provide a range of alpha blockers suitable for research in pharmacology and cardiovascular health.
Products of "Alpha blockers"
Sort by
Alfuzosin EP Impurity F
CAS:Formula:C12H16N4O2Color and Shape:White To Off-White SolidMolecular weight:248.29Silodosin Impurity 2 DiHCl (Silodosin 7-Carbonitrile DiHCl)
CAS:Formula:C25H30F3N3O3·2HClColor and Shape:Brown SolidMolecular weight:477.53 2*36.46Carvedilol-d3
CAS:Controlled ProductFormula:C24H3H23N2O4Color and Shape:Off WhiteMolecular weight:409.49Labetalol EP Impurity A HCl ((R,S)-isomer and enantiomer)
Formula:C19H23NO4·HClColor and Shape:White To Off-White SolidMolecular weight:329.40 36.46Labetalol HCl (Mixture of Diastereomers)
CAS:Formula:C19H24N2O3·HClColor and Shape:White To Off-White SolidMolecular weight:328.41 36.46Labetalol EP Impurity G HCl (Mixture of Diastereomers)
Formula:C19H23BrN2O3·HClColor and Shape:White To Off-White SolidMolecular weight:407.31 36.46Labetalol
CAS:Labetalol: mixed alpha/beta blocker for hypertension, oral or IV; affected by CYP2C19 genetics.Formula:C19H24N2O3Purity:99.87% - 99.89%Color and Shape:SolidMolecular weight:328.41(S)-Terazosin
CAS:(S)-Terazosin is an active S-enantiomer of Terazosin.Formula:C19H25N5O4Color and Shape:SolidMolecular weight:387.431-(3-Carboxy-2-pyridyl)-4-methyl-2-phenylpiperazine
CAS:Controlled ProductApplications Mirtazapine (M365000) impurity. References Reddy, T. et al.; J. Liq. Chromatogr. R. T. 31, 1204 (2008)Formula:C17H19N3O2Color and Shape:NeatMolecular weight:297.358-Hydroxy Mirtazapine
CAS:Controlled ProductApplications The main metabolite of Mirtazapine (M365000). References Delbressine, L., et al.: Clin. Drug Invest., 15, 45 (1998), Anderson, D., et al.: J. Anal. Toxicol., 23, 544 (1999), Paus, E., et al.: Ther. Drug Monit., 26, 366 (2004),Formula:C17H19N3OColor and Shape:NeatMolecular weight:281.35Silodosin Impurity 18
CAS:Formula:C25H28F3N3O5Color and Shape:White To Off-White SolidMolecular weight:507.512,3,4,5-Tetradehydro alfuzosin hydrochloride
CAS:Alfuzosin is a potent, selective, and long-acting α1A-adrenergic receptor antagonist. It is used to treat benign prostatic hyperplasia (BPH) in males. Alfuzosin is also used as an antihypertensive agent, for the treatment of pheochromocytoma, and for the treatment of benign prostatic hyperplasia in males. The hydrogenation of 2,3,4,5-tetradehydroalfuzosin to alfuzosin hydrochloride is performed by liquid hydrogenation or by hydrogenation on a palladium catalyst in a mixture of dimethylformamide and hexamethylphosphoramide. This process minimizes the formation of impurities such as 2,3,4-trimethoxy alfuzosin.Formula:C19H24ClN5O4Purity:Min. 95%Color and Shape:White PowderMolecular weight:421.88 g/molSilodosin Impurity 10
Formula:C24H33N3O4Color and Shape:White To Off-White SolidMolecular weight:427.55Dehydro Silodosin KSM-1 L-Tartrate
CAS:Formula:C22H23N3O2·C4H6O6Color and Shape:White To Off-White SolidMolecular weight:361.45 150.09(R)-Carvedilol
CAS:(R)-Carvedilol is a non-selective blocker of β/α-1. (R)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX).Formula:C24H26N2O4Purity:98%Color and Shape:SolidMolecular weight:406.472-(2-Ethoxyphenoxy)-N-[(1R)-2-(4-methoxy-3-sulfamoylphenyl)-1-methylethyl]acetamide
CAS:Color and Shape:NeatLabetalol Cyclohexyl Analog (5-{2-[(4-Cyclohexylbutan-2-yl)amino]-1-hydroxyethyl}-2-hydroxybenzamide hydrochloride)
Aromatic cyclic amides (including cyclic carbamates) and their derivatives; salts thereofFormula:C19H30N2O3·HClColor and Shape:White PowderMolecular weight:370.20232Labetalol Related Compound A (2-Hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzoic acid hydrochloride)
CAS:Aromatic amino-alcohol-phenols, aromatic amino-acid-phenols and other aromatic amino compounds with oxygen functionFormula:C19H23NO4·HClColor and Shape:Off-White SolidMolecular weight:365.13939Silodosin Impurity 16
CAS:Formula:C25H30F3N3O3Color and Shape:White To Off-White SolidMolecular weight:477.53Silodosin Impurity 12
Formula:C33H40F3N3O6Color and Shape:White To Off-White SolidMolecular weight:631.69Labetalol Hydrochloride
CAS:Aromatic cyclic amides (including cyclic carbamates) and their derivatives; salts thereofFormula:C19H24N2O3·HClColor and Shape:White Off-White Crystalline PowderMolecular weight:364.15537Silodosin-d4 Glucuronide Lithium Salt
CAS:Formula:C31H35D4F3N3O10·LiColor and Shape:White To Off-White SolidMolecular weight:674.68 6.94Carvedilol Impurity 1
CAS:Formula:C40H42N4O6Color and Shape:White To Off-White SolidMolecular weight:674.80Ref: 4Z-P-0810
Discontinued productN-Nitroso Terazosin EP Impurity C (N-Nitroso Terazosin USP Related Compound A (Free Form), N-Nitroso Doxazosin EP Impurity G, N-Nitroso Prazosin EP Impurity C)
Formula:C14H18N6O3Molecular weight:318.34Alfuzosin HCl
CAS:Formula:C19H27N5O4·HClColor and Shape:White To Off-White SolidMolecular weight:389.46 36.46Trazodone EP Impurity G HCl
Formula:C17H27ClN2O·HClColor and Shape:White To Off-White SolidMolecular weight:310.87 36.46Doxazosin mesylate
CAS:Doxazosin mesylate (UK 33274 mesylate)(UK 33274) is a quinazoline-derivative. It is a selectively antagonizes postsynaptic α1-adrenergic receptors.Formula:C24H29N5O8SPurity:99.92%Color and Shape:White To Off-White Crystalline PowderMolecular weight:547.581-(2-Bromoethoxy)-2-ethoxybenzene
CAS:Controlled ProductFormula:C10H13BrO2Color and Shape:NeatMolecular weight:245.11N2-Methyl alfuzosin
CAS:N2-Methyl alfuzosin is an impurity of Alfuzosin, a drug used to treat benign prostatic hyperplasia. It can be used as an HPLC standard for the detection and quantification of Alfuzosin in pharmaceutical products. N2-Methyl alfuzosin is a metabolite of Alfuzosin that is formed by cytochrome P450 3A4. It has been shown to have anti-inflammatory effects, which may be due to its inhibition of prostaglandin synthesis.Formula:C19H27N5O4Purity:Min. 95%Molecular weight:389.45 g/mol(R)-(+)-Carvedilol
CAS:Controlled ProductStability Hygroscopic Applications The optically active isomer of Carvedilol (C184625), a nonselective ß-adrenergic blocker with a1-blocking activity. An antihypertensive used in the treatment of congestive heart failure. Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package References Hirohashi, M., et al.: Arzneim.-Forsch., 40, 735 (1990),Formula:C24H26N2O4Color and Shape:Off White SolidMolecular weight:406.47Carvedilol Impurity 8
CAS:Formula:C12H10OColor and Shape:White To Off-White SolidMolecular weight:170.21Carvedilol Bisalkylpyrocatechol Impurity
CAS:Controlled ProductApplications A new known impurity of Carvedilol (C184625), published in Carvedilol USP monograph.Formula:C40H42N4O6Color and Shape:NeatMolecular weight:674.782-(4-Methyl-2-phenylpiperazin-1-yl)pyridine-3-carboxylic Acid
CAS:Controlled ProductFormula:C17H19N3O2Color and Shape:NeatMolecular weight:297.35Trazodone Hydrochloride Impurity G
Trazodone Hydrochloride Impurity G is a synthetic compound that is an impurity found in Trazodone Hydrochloride, CAS No. 77893-17-6. This compound has the following physical properties: MW = 284.27, mp = 227-229°C, [α] D = -33.5° (c 1.0 in water), and UV max (λ max ) = 228 nm. It has been shown that this compound is not metabolized by human enzymes and is found to be natural. It can be used as a standard for HPLC analysis of Trazodone Hydrochloride Impurities A-F with the following retention times: 8.7 min for Impurity A, 9.2 min for Impurity B, 9.9 min for Impurity C, 10.4 min for Impurity D, 11.1 min for Impurity E, and 12.3 min for Impurity F.BR>BRFormula:C17H27ClN2O·HClPurity:Min. 95%Molecular weight:347.32 g/molN2-Methyl alfuzosin hydrochloride (1:1)
CAS:N2-Methyl alfuzosin hydrochloride (1:1) is a synthetic compound that is used as an impurity standard for the drug product Alfuzosin. It has been shown to be metabolized by the liver, and its metabolites are excreted through the bile. The N2-methyl group of this compound provides a marker for metabolism studies and it has been shown to inhibit bacterial growth in vitro.Formula:C19H28ClN5O4Purity:Min. 95%Molecular weight:425.91 g/molrac-Terazosin Impurity I
Formula:C20H27N5O4Color and Shape:White To Off-White SolidMolecular weight:401.47Silodosin Metabolite-d4
Formula:C25H26F3N3O5D4Color and Shape:White To Off-White SolidMolecular weight:513.55Alfuzosin EP Impurity D
CAS:Formula:C14H21N5O2Color and Shape:White To Off-White SolidMolecular weight:291.36Phenoxybenzamine-d5 HCl
CAS:Formula:C18H17ClNOD5·HClColor and Shape:White To Off-White SolidMolecular weight:308.87 36.46N-(4-Amino-6,7-dimethoxyquinazol-2-yl)-N-methylpropylenediamine hydrochloride
CAS:N-(4-Amino-6,7-dimethoxyquinazol-2-yl)-N-methylpropylenediamine hydrochloride is an impurity that can be found in some commercially available drugs. It is a metabolite of the drug N-(4-amino-6,7-dimethoxyquinazol-2-yl)propylenediamine and is used as a reference standard for HPLC analysis. This compound has been shown to have antiplatelet activities.Formula:C14H22ClN5O2Purity:Min. 95%Molecular weight:327.81 g/mol(R)-(+)-5’-Hydroxyphenyl Carvedilol
CAS:Applications An optically active metabolite of Carvedilol (C184625), a nonselective ß-adrenergic blocker with α1-blocking activity. Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package References Sponer, G., et al.: J. Cardiovasc. Pharmacol., 9, 317 (1987), Fujimaki, M., ET AL.: Xenobiotica, 20, 1025 (1990), Ruffolo, R., et al.: Eur. J. Clin. Pharmacol., 38, S82 (1990), Schaefer, W.H., et al.: Drug Metab. Dispos., 26, 10, 958 (1998),Formula:C24H26N2O5Color and Shape:NeatMolecular weight:422.47